Engineering absorption of therapeutic compounds via colonic transporters
CA 2473802 A1 · Owner: Xenoport, Inc. · Inventors: Zerangue, Noa; Gallop, Mark A.; Cundy, Kenneth C.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods of modifying therapeutic compounds such as drugs to be substrates for active transporters expressed in epithelial cells lining the lumen of the human colon are disclosed. The transporters expressed in the human colon include the sodium dependent multi-vitamin transporter (SMVT) and , monocarboxylate transporters 1 and 4 (MCT 1 and MCT 4). The modified compounds can themselves be pharmacologically active or upon cleavage of a chemical , moiety after uptake from the colon can be metabolized to form a compound that is pharmacologically active (e.g. a prodrug). The modified compounds disclosed herein are suitable for use in extended release oral dosage forms particularly those …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 24, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.